Resumen

ESPINOSA MARTINEZ, Edgardo et al. Chronic myeloid leukemia treated with Imatinib Mesilate in patients resistant to or intolerant to recombinant a Interferon: Preliminary studies. Rev Cubana Hematol Inmunol Hemoter [online]. 2010, vol.26, n.1, pp. 12-26. ISSN 1561-2996.

Forty three patients presenting with chronic positive-Philadelphia myeloid leukemia were assessed treated with Imatinib Mesilate as a second line drug by resistance or intolerance to recombinant a Interferon. At onset, the more frequent manifestation of this condition was the splenomegalia. Imatinib Mesilate treatment was started by resistance (33; 7.6 %) or 3 or 4 degree intolerance (10; 23.3 %). The greater percentage of cytogenetic response (22; 91.7 %) and complete (11; 61.1 %) was achieved at 18 and 24 course months. The 74.3 % hadn't "molecular response and the 5.1 % yet had it before treatment; 9 (26.5 %) showed a loss of complete hematologic remission, from them, 7 deceased from disease progression. Global survival was of 90.7 %, 83.3 %, 82.6 % and 78.9 % at 5, 6, 7 and 8 course years, respectively. Global survival and free of events at three years of Imatinib Mesilate appearance was of 92.3 % and 81.8 %, respectively. There was a significant difference between survival free of events and the Sokal prognostic rate. The more frequent secondary clinical reactions were the bone and/or muscular pain and the hematologic ones were the autoimmune hemolytic anemia and the thrombocytopenia.

Palabras clave : Chronic myeloid leukemia; recombinant áInterferon; resistance; intolerance; Imatinib Mesilate.

        · resumen en Español     · texto en Español     · Español ( pdf )